{"doi":"10.1002/depr.3050030402","title":"Double‐blind multicenter comparison of fluvoxamine versus sertraline in the treatment of depressed outpatients","abstract":"<jats:title>Abstract</jats:title><jats:p>Fluvoxamine and sertraline, both selective serotonin reuptake inhibitors (SSRIs), were compared in a 5‐center, 7‐week double‐blind study in outpatients with major depression diagnosed by DSM‐III‐R criteria. Ninety‐five patients were titrated from 50 to 150 mg/day offluvoxamine (n = 49) or 50 to 200 mg/day of sertraline (n = 46). The mean dose administered in Weeks 3‐1 was 123.8 mg/day for fluvoxamine, and 137.1 mg/day for sertraline. Forty‐seven percent (47%) of fluvoxamine‐treated patients and 30% of sertraline‐treated patients were titrated to the maximum permissible dose. Fluvoxamine and sertraline were similarly effective in ameliorating depression as demonstrated by a mean reduction from baseline in the Hamilton Rating Scale for Depression (HAMD) total score of 10.61 ± 7.53 and 10.98 ± 6.08, respectively. Adverse events, mostly mild to moderate in severity, were reported for 93.5% of sertraline patients and 85.7% offluvoxamine patients. The most common events in the sertraline group were insomnia (34.8%), headache (32.6%), diarrhea (23.9%), and ejaculatory difficulty (22.2% of males), and in the fluvoxamine group, nausea (30.6%), headache (26.5%), insomnia (26.5%), and somnolence (24.5%). Significantly more patients reported sexual dysfunction in the sertraline (28%) than in the fluvoxamine (10%) group. An uncharacteristically low dropout rate due to adverse events was observed in the sertraline group (2.2%) compared with the fluvoxamine group (18.4%). The rate of withdrawal due to adverse events in the fluvoxamine group (0–2 patients/center) was comparable to that in the sertraline group (1 patient) for four of the five centers; the fifth center had 4 withdrawals in the fluvoxamine group. The differences in clinical profile of these two SSRIs provide physicians with meaningful choices in antidepressant therapy attuned to individual patient characteristics. Depression 3:163–169 (1995). © 1995 Wiley‐Liss, Inc.</jats:p>","journal":"Depression","year":1995,"id":673412,"datarank":0.5926865577872142,"base_score":3.9512437185814275,"endowment":3.9512437185814275,"self_citation_contribution":0.5926865577872142,"citation_network_contribution":0.0,"self_endowment_contribution":0.5926865577872142,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":51,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1759426,"name":"Philip T. Ninan","orcid":null,"position":1,"is_corresponding":false},{"id":1759427,"name":"James Ballenger","orcid":null,"position":2,"is_corresponding":false},{"id":1759428,"name":"R. Bruce Lydiard","orcid":null,"position":3,"is_corresponding":false},{"id":1759429,"name":"John Feighner","orcid":null,"position":4,"is_corresponding":false},{"id":1759430,"name":"William M. Patterson","orcid":null,"position":5,"is_corresponding":false},{"id":399180,"name":"John H. Greist","orcid":"0000-0002-4712-6132","position":6,"is_corresponding":false},{"id":21454,"name":"Charles B. Nemeroff","orcid":"0000-0001-7867-1160","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Double‐blind multicenter comparison of fluvoxamine versus sertraline in the treatment of depressed outpatients","abstract":null,"is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"19965766","pmcid":null,"openalex_id":null,"authors":[],"funders":[],"total_grants":0,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":"closed","license":null,"oa_locations":[],"fields_of_study":[],"mesh_terms":[],"keywords":[],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-16T13:21:40.830184Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}